Published in Cancer Weekly, June 10th, 2003
The SWOG-9504 study, led by David R. Gandara, MD, of the Southwest Oncology Group (SWOG), found that nearly 40% of patients remained alive at the 3-year follow-up.
The median survival was 26 months and the progression-free survival was 16 months, all of which surpass the results seen in a prior SWOG study (SWOG-9019) published last year in the JCO, where identical concurrent chemoradiotherapy was followed by two additional cycles of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.